BioSpace News Archive

The Multiple Myeloma Research Foundation announced that new insights related to novel targets, risk assessment, and precision medicine approaches generated through the use of the MMRF landmark CoMMpass Study will be presented at the 63rd American Society of Hematology Annual Meeting and Exposition.

Asymchem is pleased to announce its debut on the Hong Kong Exchange (HKE) through a public offering of H shares.

Anika Therapeutics, Inc. announced that on December 1, 2021, Anika granted non-statutory stock options covering an aggregate of 1,069 shares of common stock and restricted stock units covering an aggregate of 468 shares of common stock to 1 newly hired non-executive employee.

StageZero Life Sciences, Ltd., a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announced that it has engaged Richmond Hill based SRCO Professional Corporation as its auditors.

Selective hormone receptor modulators are designed as ligands to their respective receptors to provide agonist or antagonist action in specific tissues.

The demand within the global spatial genomics and transcriptomics market is expanding at a stellar pace in the years to follow.

Teriflunomide is sold under the brand name Aubagio; it is the active metabolite of leflunomide. Teriflunomide was assessed in the Phase III clinical trial TEMSO as a medication for multiple sclerosis (MS).

The veterinary endoscopes market is anticipated to grow at a significant speed in the forthcoming years.

Vifor Pharma and Angion Biomedica Corp. announced results from the exploratory phase-II GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury.

Vifor Pharma Group announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma Executive Committee as of 17 January 2022.